Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP
Maple Grove, MN – August 21, 2023 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Mesalamine Extended-Release Capsules, USP 375 mg. The mesalamine capsule market had U.S. sales of approximately $105 million for the 12 months ending June 2023 according to IQVIA. Upsher-Smith’s Mesalamine Extended-Release Capsules are AB-rated to APRISO® (mesalamine) extended-release capsules.
Product Information
|
Product |
Strength |
NDC # |
Package Size |
|
Mesalamine Extended-Release Capsules, USP |
375 mg |
0832-6056-12 |
120-count bottle |
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please refer to the full Prescribing Information for Mesalamine Extended-Release Capsules, USP here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
*APRISO is a registered trademark of Salix Pharmaceuticals, Ltd.